9 May 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Update re Loan

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 28 February 2023 in relation to the Loan Agreement entered into by the Company.

The announcement of 28 February 2023 omitted to disclose a fixed and floating charge over the Company's intellectual property to the lender as security for the proceeds of which were received on 27 February 2023. A registration of charge was registered on Companies House in relation to this matter on 28 April 2023.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 28 February 2023.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.